Clinical Trials on Atherogenic Dyslipidemia

Total 2806 results

UCSF Benioff Children's Hospital Oakland
National Cattlemen's Beef Association

Completed

Lipoprotein Effects of Substituting Beef Protein for Carbohydrate

Healthy | Cardiovascular Disease | Atherogenic Dyslipidemia

United States
Genfit

Completed

Pilot Study With GFT505 (80mg) in Atherogenic Dyslipidaemic Patients With Abdominal Obesity

Abdominal Obesity | Atherogenic Dyslipidaemia

France, Romania, Tunisia
Lewai Sharki Abdulaziz, MSc PhD
Al-Kindy College of Medicine

Completed

Extended Release Niacin and Fenofibrate for the Treatment of Atherogenic Dyslipidemia in Obese Females

Atherogenic Dyslipidemia | Obesity Associated Disorder

Iraq
GlaxoSmithKline

Completed

GW501516 In Subjects Who Have Low Level Of High-Density Lipoprotein Cholesterol

Dyslipidaemia | Dyslipidaemias

Germany, Estonia, Belgium, France, Netherlands, Denmark, Portugal, Norway, Sweden, Lithuania, Finland
UCSF Benioff Children's Hospital Oakland
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

Resistant Starch Insulin Sensitivity Trial (RESIST)

Healthy | Cardiovascular Disease | Insulin Resistance | Atherogenic Dyslipidemia

United States
GlaxoSmithKline

Completed

Study To Evaluate The Effects Of GW856553 On Endothelial Function/Vascular Compliance In Subjects With Dyslipidaemia.

Healthy Subjects | Dyslipidaemia | Dyslipidaemias

United Kingdom
Gary Van Guilder
Western Colorado University; Auckland University of Technology

Completed

The Dose-response Effects of High Intensity Functional Training on Metabolic Syndrome Risk Factors

Metabolic Syndrome | Insulin Resistance | Endothelial Dysfunction | Atherogenic Dyslipidemia

United States
Marja-Riitta Taskinen
Göteborg University

Enrolling by invitation

Genetic Pathways Leading to Fatty Liver and Atherogenic Dyslipidemia (VARKIN)

Insulin Resistance | Non-alcoholic Fatty Liver | Atherogenic Dyslipidemia

Finland, Sweden
Abbott

Completed

Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood

Dyslipidemias | Coronary Heart Disease | Mixed Dyslipidemia | Combined (Atherogenic) Dyslipidemia

United States
University Ghent
Research Foundation Flanders

Recruiting

The Effect of Cognitive Dual-task Rehabilitation on Arthrogenic Muscle Responses After ACL Reconstruction (AMIRA)

Anterior Cruciate Ligament Reconstruction | ACL Injury | Athrogenic Muscle Responses | Arthrogenic Muscle Inhibition

Belgium
Xention Ltd

Completed

Study of the Electrocardiographic Effects of TA-8995

Dyslipidaemia

United Kingdom
AstraZeneca

Completed

Statin Therapy Results in the Real World Practice in the Czech Republic (STEP)

Dyslipidaemia

Czech Republic
AstraZeneca

Completed

A Study of AZD8233 in Participants With Dyslipidemia

Dyslipidaemia

Denmark, United States, Slovakia
Novartis Pharmaceuticals

Completed

Safety and Pharmacokinetis of TAP311 in Dyslipidemic Patients

Dyslipidaemia

Jordan, United States, Taiwan
AstraZeneca

Completed

48-wk Open Label Phase IIIb to Evaluate Efficacy and Safety

Dyslipidaemia
GlaxoSmithKline

Completed

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin

Dyslipidemias | Dyslipidaemias

United States
GlaxoSmithKline

Completed

Dyslipidemia Study Investigating The Increase In "Good Cholesterol"

Dyslipidaemias

United States, Canada
GlaxoSmithKline

Completed

A Study in Healthy Volunteers of Single Doses of Orally Administered Investigational Product to Investigate Safety, Tolerability, and Pharmacokinecs.

Dyslipidaemias

United States
Novo Nordisk A/S

Recruiting

A Study to Look at How Safe a New Medicine (NNC0491-6075) is in Healthy People and in Participants With High Levels of Fat in the Blood

Healthy Volunteers | Dyslipidaemia

United States
AstraZeneca

Completed

Centralized Pan-Russian Survey on the Undertreatment of Hypercholesterolemia (CEPHEUS)

Dyslipidaemia

Russian Federation
AstraZeneca

Completed

Treatment of Hypercholesterolaemia in South Asian Subjects (IRIS) (IRIS)

Hypercholesterolemia | Dyslipidaemia
GlaxoSmithKline

Completed

Study to Test GSK256073 in Patients With Dyslipidemia

Dyslipidemias | Dyslipidaemias

United States
GlaxoSmithKline

Completed

Repeat Dose Food Effect Study of GSK256073F in Healthy Adult Subjects

Dyslipidaemias

United States
AstraZeneca

Completed

Treatment of Hypercholesterolaemia in Hispanic Subjects (STARSHIP) (STARSHIP)

Hypercholesterolemia | Dyslipidaemia
AstraZeneca

Completed

CEntralized Pan-Russian Survey of tHE Undertreatment of hypercholeSterolemia II (CEPHEUS II) (CEPHEUSII)

Dyslipidaemia

Russian Federation
Xention Ltd

Completed

Bioequivalence Study of Capsule and Tablet Formulations of TA-8995

Dyslipidaemia

United Kingdom
AstraZeneca

Completed

Rosuvastatin Versus Atorvastatin in the Treatment of Hypercholesterolaemia in African American Subjects(ARIES) (ARIES)

Hypercholesterolemia | Dyslipidaemia
GlaxoSmithKline

Completed

A Second Study to Determine the Effect of GSK256073A on HVTs

Healthy Subjects | Dyslipidaemias

United States
GlaxoSmithKline

Completed

Study Of Pharmacokinetics and Pharmacodynamics Effects Of GSK256073A On Healthy Volunteers

Healthy Subjects | Dyslipidaemias

United States
AstraZeneca

Completed

IIIb 6 Week Open Label Multicentre Rosuvastatin & Simvastatin

Fredrickson Type IIa & Type IIb Dyslipidaemia
NeuroBo Pharmaceuticals Inc.

Completed

A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)

Severe Hypertriglyceridemia | Mixed Dyslipidaemia

United States, Canada
University Health Network, Toronto
Canadian Institutes of Health Research (CIHR)

Completed

Regulation of Intestinal and Hepatic Lipoprotein Secretion by Resveratrol

Insulin Resistance | Dyslipidaemia

Canada
GlaxoSmithKline

Completed

A Study To See If GSK256073A Can Block Niacin-Induced Flushing In Healthy Volunteers

Healthy Subjects | Dyslipidaemias

United States
GlaxoSmithKline

Completed

An Exploratory Study To Look At The Effect Of Two Investigational Drugs On Body Fat And Inflammation

Obesity | Hypercholesterolemia | Dyslipidaemias

United States
GlaxoSmithKline

Terminated

Effect Of GW501516X On How The Heart Obtains And Uses Energy

Heart Failure | Dyslipidaemias

United States
Hanlim Pharm. Co., Ltd.

Recruiting

An Observational Study on the Identification of Prescription Patterns of STAFEN Cap

Mixed Dyslipidemia

Korea, Republic of
IlDong Pharmaceutical Co Ltd

Not yet recruiting

A Post-marketing Surveillance to Assess Safety and Efficacy of Rosuvatatin/Ezetimibe

Mixed Dyslipidemia
Arrowhead Pharmaceuticals

Completed

Study of ARO-APOC3 in Adults With Mixed Dyslipidemia (MUIR)

Mixed Dyslipidemia

United States, Australia, Poland, New Zealand, Canada, Hungary
Provident Clinical Research
Reliant Pharmaceuticals

Completed

An Evaluation of Simvastatin Plus Omacor Compared to Simvastatin Plus Placebo in Subjects With Mixed Dyslipidemia

Mixed Dyslipidemia
Arrowhead Pharmaceuticals

Active, not recruiting

Study of ARO-ANG3 in Adults With Mixed Dyslipidemia (ARCHES-2)

Mixed Dyslipidemia

United States, Australia, Canada, New Zealand
Yooyoung Pharmaceutical Co., Ltd.

Completed

Clinical Trial to Evaluate the Efficacy and Safety of Pravafenix Cap to Verify the Superiority Than Atorvastatin

Combined Dyslipidemia

Korea, Republic of
Société des Produits Nestlé (SPN)

Completed

Effect of a Low Fat Milk Product on Lipids Profile in Dyslipidemia Subjects (Lipidown)

Primary Dyslipidemia

China
Provident Clinical Research
Reliant Pharmaceuticals

Unknown

An Open-Label Extension to Assess the Continued Efficacy of Omacor Plus Simvastatin

Mixed Dyslipidemia
Kowa Research Institute, Inc.

Completed

Prevail-Us: A Study Of Pitavastatin 4 mg Vs. Pravastatin 40 mg In Patients With Primary Hyperlipidemia Or Mixed Dyslipidemia (PREVAIL-US)

Mixed Dyslipidemia | Primary Dyslipidemia

United States
Addpharma Inc.

Recruiting

A Study to Evaluate the Efficacy and Safety of AD-218

Mixed Dyslipidemia

Korea, Republic of
University of Guadalajara

Completed

Bezafibrate Plus Berberine in Mixed Dyslipidemia

Mixed Dyslipidemia

Mexico
Esperion Therapeutics, Inc.

Completed

A Multiple Ascending Dose Study of ETC-1002 in Subjects With Mild Dyslipidemia

Mild Dyslipidemia

United States
Hanlim Pharm. Co., Ltd.

Completed

A Clinical Trial to Evaluate the Efficacy and Safety of Pitavastatin/Fenofibrate in Complex-dyslipidemia

Complex-dyslipidemia
Abbott

Completed

A Year 2, Safety Extension Study of the Combination of ABT-335 and Statin Therapy for Subjects With Mixed Dyslipidemia

Mixed Dyslipidemia

United States
Chong Kun Dang Pharmaceutical

Completed

CKD-337 Drug Interaction Study

Dyslipidemia (Fredrickson Type Ⅱa) | Dyslipidemia (Fredrickson Type Ⅱb)

Korea, Republic of

Clinical Trials on Atherogenic Dyslipidemia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Oman

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations